BioCentury | Nov 22, 2019
Emerging Company Profile

Morphiex’s antisense take on CD47 aims for more than eating

...dialing down the interaction between CD47 on tumors and SIRPA on macrophages, Morphiex lead candidate MBT-001...
...development agreement (CRADA) with NCI and the National Institutes of Health to accelerate development of MBT-001...
...MBT-001 would only block the glycoprotein’s tumor-promoting interaction with CD47, and not its other receptors. MBT-001...
BioCentury | Feb 14, 2013
Cover Story

Cancer target selection pressure

...still are not good inhibitors." The algorithm also may miss druggable targets. The methyllysine-binding protein l(3)mbt-like...
BioCentury | Apr 14, 2008
Clinical News

Cubicin daptomycin regulatory update

...Cubist issued a "Dear Healthcare Professional" letter warning that an impurity identified as 2-mercaptobenzothiazole (MBT) has...
BioCentury | Aug 16, 2004
Company News

MediGene, Munich Biotech deal

...12.5 million ($15.4 million). The acquisition includes Munich's EndoTag tumor endothelial cell targeting technology and MBT-0206...
...Munich's VCs paid EUR 4 million in cash to MDG to support further development of MBT-0206...
BioCentury | Aug 13, 2004
Company News

MediGene buys Munich Biotech assets

...12.5 million ($15.4 million). The acquisition includes Munich's EndoTag tumor endothelial cell targeting technology and MBT-0206...
...Munich’s VCs paid EUR 4 million in cash to MDG to support further development of MBT-0206...
BioCentury | Jun 4, 2004
Company News

Munich Biotech files for insolvency

...Cancer play Munich Biotech (Neuried, Germany) said it filed for insolvency last week. The company's MBT-0206...
...in Phase II testing to treat metastatic breast cancer and metastatic pancreatic cancer. The company's MBT-0312...
BioCentury | Mar 29, 2004
Clinical News

MBT-0206: Phase I data

...for metastatic breast cancer and metastatic pancreatic cancer. Munich Biotech AG , Neuried, Germany Product: MBT-0206...
BioCentury | Jan 26, 2004
Clinical News

MBT-0206: Phase II

...to the trial if undisclosed milestones are met. Munich Biotech AG , Neuried, Germany Product: MBT-0206...
BioCentury | Jan 26, 2004
Clinical News

MBT-0206: Phase II

...to the trial if undisclosed milestones are met. Munich Biotech AG , Neuried, Germany Product: MBT-0206...
BioCentury | Jan 20, 2004
Clinical News

Munich starts Phase II cancer trials

...Munich Biotech (Neuried, Germany) began two open label, European Phase II trials of MBT-0206 in about...
...milestones are met. The breast cancer trial will assess tumor response in patients treated with MBT-0206...
...MBT-0206 plus gemcitabine. The company would not comment on how long the trials will take. MBT-0206...
Items per page:
1 - 10 of 20
BioCentury | Nov 22, 2019
Emerging Company Profile

Morphiex’s antisense take on CD47 aims for more than eating

...dialing down the interaction between CD47 on tumors and SIRPA on macrophages, Morphiex lead candidate MBT-001...
...development agreement (CRADA) with NCI and the National Institutes of Health to accelerate development of MBT-001...
...MBT-001 would only block the glycoprotein’s tumor-promoting interaction with CD47, and not its other receptors. MBT-001...
BioCentury | Feb 14, 2013
Cover Story

Cancer target selection pressure

...still are not good inhibitors." The algorithm also may miss druggable targets. The methyllysine-binding protein l(3)mbt-like...
BioCentury | Apr 14, 2008
Clinical News

Cubicin daptomycin regulatory update

...Cubist issued a "Dear Healthcare Professional" letter warning that an impurity identified as 2-mercaptobenzothiazole (MBT) has...
BioCentury | Aug 16, 2004
Company News

MediGene, Munich Biotech deal

...12.5 million ($15.4 million). The acquisition includes Munich's EndoTag tumor endothelial cell targeting technology and MBT-0206...
...Munich's VCs paid EUR 4 million in cash to MDG to support further development of MBT-0206...
BioCentury | Aug 13, 2004
Company News

MediGene buys Munich Biotech assets

...12.5 million ($15.4 million). The acquisition includes Munich's EndoTag tumor endothelial cell targeting technology and MBT-0206...
...Munich’s VCs paid EUR 4 million in cash to MDG to support further development of MBT-0206...
BioCentury | Jun 4, 2004
Company News

Munich Biotech files for insolvency

...Cancer play Munich Biotech (Neuried, Germany) said it filed for insolvency last week. The company's MBT-0206...
...in Phase II testing to treat metastatic breast cancer and metastatic pancreatic cancer. The company's MBT-0312...
BioCentury | Mar 29, 2004
Clinical News

MBT-0206: Phase I data

...for metastatic breast cancer and metastatic pancreatic cancer. Munich Biotech AG , Neuried, Germany Product: MBT-0206...
BioCentury | Jan 26, 2004
Clinical News

MBT-0206: Phase II

...to the trial if undisclosed milestones are met. Munich Biotech AG , Neuried, Germany Product: MBT-0206...
BioCentury | Jan 26, 2004
Clinical News

MBT-0206: Phase II

...to the trial if undisclosed milestones are met. Munich Biotech AG , Neuried, Germany Product: MBT-0206...
BioCentury | Jan 20, 2004
Clinical News

Munich starts Phase II cancer trials

...Munich Biotech (Neuried, Germany) began two open label, European Phase II trials of MBT-0206 in about...
...milestones are met. The breast cancer trial will assess tumor response in patients treated with MBT-0206...
...MBT-0206 plus gemcitabine. The company would not comment on how long the trials will take. MBT-0206...
Items per page:
1 - 10 of 20